Results 11 to 20 of about 3,123 (163)

In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement

Antibiotics, 2023
Based on previous studies by our group in which we demonstrated that dalbavancin loaded in bone cement had good elution capacity for the treatment of biofilm-related periprosthetic infections, we now assess the anti-biofilm activity of dalbavancin and ...
Mar Sánchez-Somolinos, Marta Díaz-Navarro, Antonio Benjumea, José Matas, Javier Vaquero, Patricia Muñoz, Pablo Sanz-Ruíz, María Guembe   +7 more
doaj   +2 more sources

The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa [PDF]

Antibiotics, 2022
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful nodules, abscesses, and fistulas, localized to the areas of the folds where apocrine glands are present: the armpits, groin, inframammary region, and genital or
Elisa Molinelli, Claudia Sapigni, Giovanni Marco D’Agostino, Valerio Brisigotti, Giulio Rizzetto, Ivan Bobyr, Oscar Cirioni, Andrea Giacometti, Lucia Brescini, Sara Mazzanti, Annamaria Offidani, Oriana Simonetti   +11 more
doaj   +2 more sources

Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review

Journal of Global Antimicrobial Resistance, 2021
: Objectives: Dalbavancin is a long-lasting lipoglycopeptide active against Gram-positive bacteria, especially methicillin-resistant staphylococci. Few data are available on dalbavancin use for treatment of prosthetic joint infections (PJIs).
Morgan Matt, Clara Duran, Johan Courjon, Romain Lotte, Vincent Le Moing, Boris Monnin, Patricia Pavese, Pascal Chavanet, Lydie Khatchatourian, Pierre Tattevin, Vincent Cattoir, Catherine Lechiche, Gabriella Illes, Flore Lacassin-Beller, Eric Senneville, Aurélien Dinh   +15 more
doaj   +2 more sources

Determination of the Elution Capacity of Dalbavancin in Bone Cements: New Alternative for the Treatment of Biofilm-Related Peri-Prosthetic Joint Infections Based on an In Vitro Study

Antibiotics, 2022
Antibiotic-loaded bone cement is the most widely used approach for the treatment of biofilm-induced septic sequelae in orthopedic surgery. Dalbavancin is a lipoglycopeptide that acts against Gram-positive bacteria and has a long half-life, so we aimed to
Mar Sánchez-Somolinos, Marta Díaz-Navarro, Antonio Benjumea, Marta Tormo, José Matas, Javier Vaquero, Patricia Muñoz, Pablo Sanz-Ruíz, María Guembe   +8 more
doaj   +2 more sources

Dalbavancin is thermally stable at clinically relevant temperatures against methicillin-sensitive Staphylococcus Aureus [PDF]

Journal of Bone and Joint Infection, 2023
Introduction: While the rate of orthopaedic infections has remained constant over the years, the burden on healthcare systems continues to rise with an aging population.
A. K. Hoyt, P. Lawler, M. Bostrom, M. Bostrom, A. V. Carli, A. V. Carli, A. E. Levack, A. E. Levack   +7 more
doaj   +3 more sources

Study of the release kinetics of dalbavancin from bone allografts

Journal of Materials Science: Materials in Medicine
Bone infections are common and difficult to treat, and secondary bone defects, which are often observed, may require a bone allograft. In this case, the surgeon will add antibiotics (usually vancomycin) in direct contact with the bone graft during the ...
Roger Erivan, Nicolas Bourzat, Mouloud Yessaad, Guillaume Villatte, Stéphane descamps, Stéphane Boisgard, Philip Chennell   +6 more
doaj   +2 more sources

Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs [PDF]

Drug Design, Development and Therapy, 2021
Milo Gatti,1,2 Massimo Andreoni,3,4 Federico Pea,1,2 Pierluigi Viale1,5 1Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy; 2SSD Clinical Pharmacology, IRCCS Azienda Ospedaliero-Universitaria di ...
Gatti M, Andreoni M, Pea F, Viale P
doaj   +2 more sources

Dalbavancin utilization registry investigating value and effectiveness (DRIVE): Outcomes report on real-world use

Clinical Infection in Practice
Objectives: Dalbavancin has potent activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus, and is approved for treatment of acute bacterial skin and skin structure infections (ABSSSI).
Bruce M. Jones, Kerry O. Cleveland, Pedro L. Gonzalez, Urania Rappo, Todd Riccobene, Rosie D. Lyles   +5 more
doaj   +2 more sources

Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review [PDF]

, 2021
Dalbavancin (DAL) is a lipoglycopeptide with bactericidal activity against a very wide range of Gram-positive microorganisms. It also has unique pharmacokinetic properties, namely a prolonged half-life (around 181 h), which allows a convenient weekly ...
Luis Buzón-Martín, Emilia Cercenado, Zollner Schwetz, Ines, Ines Zollner-Schwetz, Selma Tobudic, Jaime Lora-Tamayo, Cercenado Mansilla, Emilia, Lora-Tamayo Morillo-Velarde, Jaime, Tobudic, Selma, Buzón Martín, Luis   +9 more
core   +1 more source

Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study [PDF]

Infectious Diseases and Therapy
Introduction Long-acting lipoglycopeptides such as dalbavancin may have utility in patients with Gram-positive bloodstream infections (BSI), particularly in those with barriers to discharge or who require prolonged parenteral antibiotic courses.
Nicholas Rebold, Sara Alosaimy, Jeffrey C. Pearson, Brandon Dionne, Ahmad Taqi, Abdalhamid Lagnf, Kristen Lucas, Mark Biagi, Nicholas Lombardo, Joshua Eudy, Daniel T. Anderson, Monica V. Mahoney, Wesley D. Kufel, Joseph A. D’Antonio, Bruce M. Jones, Jeremy J. Frens, Tyler Baumeister, Matthew Geriak, George Sakoulas, Dimitrios Farmakiotis, Dino Delaportas, Jeremy Larew, Michael P. Veve, Michael J. Rybak   +23 more
doaj   +2 more sources